INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,458,520 | -72.4% | 28,000 | -72.0% | 0.76% | -71.7% |
| Q4 2022 | $5,292,000 | +13.7% | 100,000 | 0.0% | 2.69% | +57.6% |
| Q3 2022 | $4,653,000 | +8.7% | 100,000 | +33.3% | 1.71% | -0.4% |
| Q2 2022 | $4,281,000 | +210.9% | 75,000 | +233.3% | 1.71% | +271.6% |
| Q1 2022 | $1,377,000 | -54.1% | 22,500 | -74.5% | 0.46% | -44.6% |
| Q1 2021 | $2,997,000 | -38.5% | 88,326 | -42.4% | 0.83% | -54.3% |
| Q4 2020 | $4,876,000 | – | 153,348 | – | 1.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |